What is the 13F Pro Quality Score for NPCE?

13F Pro ranks NeuroPace Inc (NPCE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NPCE's current score at https://13fpro.ai/company/NPCE (free sign-up required for the full ranking).

Where does 13F Pro source NPCE data?

All NeuroPace Inc fundamentals and ownership data come directly from SEC EDGAR. NeuroPace Inc files with the SEC under CIK 1528287. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NPCE in?

NeuroPace Inc (NPCE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NPCE research updated on 13F Pro?

NPCE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NeuroPace Inc(NPCE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1528287 NPCE stock profile & AI dashboard →

13F Pro Quality Score

32.4/100

Rank #2,429 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

80.8/100

Profitability

19.2/100

Balance Sheet

11.6/100

Earnings Quality

31.2/100

Free Cash Flow

16.0/100

Institutional Flow

16.6/100

Revenue Scale

16.1/100

Dilution Risk

15.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NPCE Scores 32/100

exact factor attribution · 2026-09-11

NPCE's composite is driven by revenue growth, held back by free cash flow and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.2 pts

81th pct

Earnings growth

+0.2 pts

54th pct

Institutional flow

-1.7 pts

17th pct

Shareholder dilution

-1.7 pts

15th pct

Earnings quality

-1.9 pts

31th pct

Capital efficiency

-3.8 pts

12th pct

Profitability

-4.6 pts

19th pct

Scale

-5.1 pts

16th pct

Free cash flow

-5.1 pts

16th pct

Latest change (2026-08-11): 31 → 30 · ↓ Revenue growth 81→65

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NPCE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for NeuroPace Inc (NPCE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NPCE at 32.4/100 on a 32-signal composite quality model, placing it at rank #2,429 of 2,961 stocks — the bottom half of the AI-ranked universe. NPCE scores in the top quartile across revenue growth (80.8). Areas of concern include balance sheet strength (11.6) and free cash flow (16.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NeuroPace Inc reports quarterly revenue of $22.8M, net income of $-6.2M, an operating margin of -22.5%. Top institutional holders of NPCE by reported 13-F value include Polar Capital Plc, Soleus Capital Management, L.P., First Light Asset Management, based on the most recent SEC filings. NPCE trades on the Nasdaq exchange and files with the SEC under CIK 1528287. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NPCE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NeuroPace Inc directly from SEC EDGAR. NeuroPace Inc's 13F Pro composite quality score has ranged between 11 and 34 since 2022, currently 32.4 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.

✦

Fun facts about NeuroPace Inc

Quirks, history, and lore behind NPCE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the range of tens of millions of dollars — this is not a blockbuster yet — with a focus on growing its implanted patient base rather than near-term profit.
3
The History
Founded in the late 1990s, it spent years navigating FDA approval before finally bringing its flagship device to market — a journey measured in decades, not quarters.
4
The Secret
Its device lives inside the skull, continuously monitoring brain activity and delivering on-demand electrical stimulation only when it detects a seizure coming — essentially a pacemaker for the brain.
5
The Lore
The company targets drug-resistant epilepsy patients who have failed multiple medications — a population of millions with very few options left and nowhere else to turn.
6
The Giveaway
Its RNS System — the only closed-loop responsive neurostimulation device approved by the FDA for epilepsy — is literally a tiny computer bolted to your brain that fires electricity when it senses trouble.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$22.8M

Net Income

Q2 2026

$-6.2M

Free Cash Flow

Q2 2026

$-4.0M

Operating Margin

Q2 2026

-22.5%

ROIC

Q2 2026

-29.0%

D/E Ratio

Q2 2026

4.97

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+25.1% YoY

$100.0MFY 2025

FY22 $45.5MFY23 $65.4MFY24 $79.9MFY25 $100.0M

Net Income

+20.9% YoY

$-21.5MFY 2025

FY22 $-47.1MFY23 $-33.0MFY24 $-27.1MFY25 $-21.5M

Operating Income

+24.6% YoY

$-16.3MFY 2025

FY22 $-40.8MFY23 $-27.2MFY24 $-21.7MFY25 $-16.3M

EPS (Diluted)

+29.0% YoY

$-0.66FY 2025

FY22 $-1.91FY23 $-1.27FY24 $-0.93FY25 $-0.66

Total Assets

+11.5% YoY

$105.6MFY 2025

FY22 $114.1MFY23 $107.7MFY24 $94.6MFY25 $105.6M

Total Debt

-1.1% YoY

$58.9MFY 2025

FY22 $52.9MFY23 $57.0MFY24 $59.5MFY25 $58.9M

Op. Cash Flow

+38.7% YoY

$-11.0MFY 2025

FY22 $-36.9MFY23 $-19.7MFY24 $-17.9MFY25 $-11.0M

Free Cash Flow

+37.9% YoY

$-11.3MFY 2025

FY22 $-37.5MFY23 $-19.9MFY24 $-18.3MFY25 $-11.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$100.0M +25.1%	$79.9M +22.1%	$65.4M +43.7%	$45.5M +0.7%	$45.2M +9.8%	$41.1M
Net Income	$-21.5M +20.9%	$-27.1M +17.6%	$-33.0M +30.0%	$-47.1M -30.5%	$-36.1M -48.6%	$-24.3M
Operating Income	$-16.3M +24.6%	$-21.7M +20.3%	$-27.2M +33.4%	$-40.8M -71.9%	$-23.7M -81.9%	$-13.1M
EPS (Diluted)	$-0.66 +29.0%	$-0.93 +26.8%	$-1.27 +33.5%	$-1.91 +12.0%	$-2.17 +98.2%	$-117.85
Total Assets	$105.6M +11.5%	$94.6M -12.1%	$107.7M -5.7%	$114.1M -14.6%	$133.6M +138.7%	$56.0M
Total Debt	$58.9M -1.1%	$59.5M +4.5%	$57.0M +7.6%	$52.9M +6.2%	$49.8M -5.7%	$52.9M
Operating Cash Flow	$-11.0M +38.7%	$-17.9M +8.9%	$-19.7M +46.6%	$-36.9M -50.0%	$-24.6M -13.7%	$-21.6M
Free Cash Flow	$-11.3M +37.9%	$-18.3M +8.1%	$-19.9M +47.0%	$-37.5M -50.1%	$-25.0M -15.2%	$-21.7M

Get alerted when NPCE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NeuroPace Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NPCE

Polar Capital Holdings Plc
$52.4M3,298,104 sh
Soleus Capital Management, L.P.
$46.3M2,911,122 sh
First Light Asset Management, LLC
$45.5M2,861,167 sh
MORGAN STANLEY
$42.2M2,654,391 sh
BlackRock, Inc.
$39.4M2,477,603 sh
ORBIMED ADVISORS LLC
$23.9M1,505,125 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$23.0M1,447,391 sh
VANGUARD CAPITAL MANAGEMENT LLC
$19.5M1,227,072 sh
DEUTSCHE BANK AG\
$14.9M938,919 sh
ARMISTICE CAPITAL, LLC
$11.0M692,000 sh

Fund	Value	Shares
Polar Capital Holdings Plc	$52.4M	3,298,104
Soleus Capital Management, L.P.	$46.3M	2,911,122
First Light Asset Management, LLC	$45.5M	2,861,167
MORGAN STANLEY	$42.2M	2,654,391
BlackRock, Inc.	$39.4M	2,477,603
ORBIMED ADVISORS LLC	$23.9M	1,505,125
DRIEHAUS CAPITAL MANAGEMENT LLC	$23.0M	1,447,391
VANGUARD CAPITAL MANAGEMENT LLC	$19.5M	1,227,072
DEUTSCHE BANK AG\	$14.9M	938,919
ARMISTICE CAPITAL, LLC	$11.0M	692,000

Companies Similar to NPCE

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CERS

CERUS CORP

AI score

Very similar · 8 shared holders

Soleus Capital Management, L.P.SILVERCREST ASSET MANAGEMENT GROUP LLC KOTLER KEVIN

TLSI

TriSalus Life Sciences, Inc.

AI score

Very similar · 3 shared holders

First Light Asset Management, LLC KOTLER KEVIN HighMark Wealth Management LLC

BBNX

Beta Bionics, Inc.

AI score

Very similar · 4 shared holders

Soleus Capital Management, L.P.Kent Lake PR LLC EntryPoint Capital, LLC

AXGN

Axogen, Inc.

AI score

Very similar · 12 shared holders

Polar Capital Holdings Plc First Light Asset Management, LLC DRIEHAUS CAPITAL MANAGEMENT LLC

LUNG

Pulmonx Corp

AI score

Very similar · 4 shared holders

Soleus Capital Management, L.P.Kent Lake PR LLC KOTLER KEVIN

SIBN

SI-BONE, Inc.

AI score

Very similar · 8 shared holders

First Light Asset Management, LLC SILVERCREST ASSET MANAGEMENT GROUP LLC Kent Lake PR LLC

KRMD

KORU Medical Systems, Inc.

AI score

Similar quality profile · 2 shared holders

First Light Asset Management, LLC HighMark Wealth Management LLC

TWST

Twist Bioscience Corp

AI score

Similar quality profile · 8 shared holders

First Light Asset Management, LLC DRIEHAUS CAPITAL MANAGEMENT LLC ARMISTICE CAPITAL, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NPCE on your watchlist

Track score changes the day NeuroPace Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NPCE a good stock to buy?

13F Pro's AI-powered analysis of NeuroPace Inc (NPCE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NPCE are available on the NPCE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NPCE is classified as a small company.

Which hedge funds own NPCE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NPCE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NeuroPace Inc's investment landscape.